Innoviva Inc
Change company Symbol lookup
Select an option...
INVA Innoviva Inc
APT Alpha Pro Tech Ltd
PTC PTC Inc
AIC Arlington Asset Investment Corp
PSAGW Property Solutions Acquisition Corp II *W EXP 03/01/2026
AMZN Amazon.com Inc
GSK GlaxoSmithKline PLC
TSLA Tesla Inc
MMD MainStay MacKay DefinedTerm Municipal Opportunities Fund
APSG Apollo Strategic Growth Capital
Go

Health Care : Pharmaceuticals | Small Cap Blend
Company profile

Innoviva, Inc. is a company with a portfolio of royalties and other healthcare assets. Its royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including, RELVAR/BREO ELLIPTA (fluticasone furoate/ vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI) and TRELEGY ELLIPTA (the combination FF/UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and royalties from the sales of ANORO and ELLIPTA. RELVAR/BREO is a once-daily combination medicine consisting of a LABA, vilanterol (VI), and an inhaled corticosteroid (ICS) and fluticasone furoate (FF). ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, VI. TRELEGY ELLIPTA a once-daily combination medicine consisting of an ICS, LAMA and LABA.

Postmarket

Last Trade
Delayed
$0.00
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$16.71
Day's Change
0.04 (0.24%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
16.79
Day's Low
16.61
Volume
(Light)
Volume:
312,642

10-day average volume:
677,789
312,642

Moderna to invest $500 million in 'state-of-the-art' mRNA vaccine factory in Africa

2:44 am ET October 7, 2021 (MarketWatch)
Print

By Barbara Kollmeyer

Amid global criticism over a lack of vaccine availabilty in developing nations, Moderna on Thursday announced it will build a "state-of-the-art" mRNA facility in Africa, aimed at producing 500 million doses of vaccines a year.

The biotechnology company (MRNA)responsible for messenger RNA therapeutics and vaccines that have been at the forefront of the battle against the COVID-19 pandemic, said it will invest up to $500 million in a new facility. The site and country selection process is expected to begin soon, and the facility would handle drug substance manufacturing, and potentially fill/finish and packaging capbilities, the company said.

"While we are still working to increase capacity in our current network to deliver vaccines for the ongoing pandemic in 2022, we believe it is important to invest in the future," said Stephane Bancel, Moderna's chief executive officer, in a statement. "We expect to manufacture our COVID-19 vaccine as well as additional products within our mRNA vaccine portfolio at this facility."

Moderna's pipeline includes 20 candidates including vaccines against respiratory viruses, vaccines against latent viruses and vaccines against threats to global public health.

The company has provided more than 500 million doses of its COVID vaccine to date, but Africa remains one of the least vaccinated continents in the world. According to The New York Times vaccine tracker, in many African countries, less than 1% of the population is fully vaccinated.

The World Health Organization and other global aid groups have been highly critical of the slow pace of global vaccinations and lack of shots in poorer nations, versus wealthier, where booster shots are now starting to roll out.

Moderna shares have skyrocketed 189% this year, compared to a 13% rise for the Nasdaq Composite .

-Barbara Kollmeyer

	

(END) Dow Jones Newswires

October 07, 2021 02:44 ET (06:44 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.